Iron Deficiency Injectable Global Market Report 2024

The global iron deficiency injectable market has grown rapidly in recent years. It will grow from $12.75 billion in 2023 to $14.06 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to high prevalence of iron deficiency anemia treatments, bariatric surgery patients, pediatric and adolescent patients, growing pregnancy.

The global iron deficiency injectable market is expected to see rapid growth in the next few years. It will grow to $20.68 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to geriatric population, global health initiatives, government initiatives, incresing treatments for chronic conditions, rapid iron replenishment. Major trends in the forecast period include advances in iron formulations, digital health solutions, advancements in iron deficiency injectable therapy, adoption of iron-based drugs,.

The iron deficiency injectables market is anticipated to experience growth due to the increasing prevalence of polycystic ovary syndrome (PCOS). PCOS is a commonly occurring hormonal disorder that predominantly affects individuals with ovaries, primarily women in their reproductive years. PCOS often leads to iron overload, resulting in excessive menstrual bleeding and subsequent anemia in affected patients. Injectable iron deficiency medications offer an effective solution to address this condition. For example, as of June 2023, the World Health Organization, a specialized health agency based in the United States, estimates that PCOS affects approximately 8-13% of reproductive-aged women globally, with 70% of cases remaining undiagnosed. Hence, the rising prevalence of polycystic ovary syndrome (PCOS) serves as a driving force behind the growth of the iron deficiency injectables market.

The substantial prevalence of malnutrition is a key driver behind the expansion of the iron deficiency injectable market. Malnutrition signifies a health condition marked by an imbalance between the intake of essential nutrients and the nutritional requirements of the body. Iron deficiency injectables play a crucial role in addressing malnutrition by swiftly replenishing iron stores and delivering a concentrated dose of iron that is readily absorbed into the bloodstream, enabling the rapid correction of the deficiency. For example, in March 2023, the California Department of Public Health reported an increase in malnutrition-related deaths to 1,406 in 2022, marking a notable 22.36% surge compared to the 1,149 deaths recorded in 2021. As a result, the heightened prevalence of malnutrition is expected to drive the future growth of the iron deficiency injectable market.

The presence of alternative treatment options is a factor that may impede the growth of the iron deficiency injectables market in the forecast period. Alternative treatments encompass non-conventional approaches to addressing a medical condition. Conventional prescription drug therapies used for managing iron deficiency anemia include ferrous sulfate, erythropoietin (EPO) injections, and iron infusion therapy. For instance, as recommended by the American Metabolic and Bariatric Associations, oral administration remains the primary choice for treating patients with iron-deficiency anemia. Consequently, the availability of alternative treatments presents a challenge to the expansion of the market for iron deficiency injectables.

Prominent companies operating in the iron deficiency injectables market are actively engaged in the development of innovative therapies, such as INJECTAFER, to maintain their competitive standing in the market. For instance, in June 2023, Daiichi Sankyo Company, a U.S.-based healthcare company, in collaboration with American Regent Inc., a U.S.-based injectables manufacturer, introduced INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency. This innovative therapy received approval from the Food and Drug Administration (FDA), a U.S. government agency. INJECTAFER is recognized as the first and only intravenous iron replacement therapy approved for adult patients with chronic and progressive heart failure. It has undergone rigorous evaluation through more than 40 clinical trials involving over 8,800 participants from various countries, demonstrating its effectiveness in patients, including adults and pediatric individuals with iron-deficient anemia and heart failure.

In August 2022, CSL Limited, an Australian-based biotechnology company specializing in the production of iron deficiency injectables, completed the acquisition of Vifor Pharma for an undisclosed sum. This strategic acquisition reinforces CSL's commitment to patient care and enhances its capability to provide advanced medications. Vifor Pharma, headquartered in Switzerland, is a pharmaceutical company renowned for its offerings in the field of iron deficiency injectables.

Major players in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Aetna Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, AstraZeneca PLC, GSK PLC, Fresenius Medical Care, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, Cipla Limited, Emcure Pharmaceuticals Ltd., AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH , Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc., Galen Medical Group.

North America was the largest region in the iron deficiency injectable market in 2023. The regions covered in iron deficiency injectable report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the iron deficiency injectable market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of iron deficiency injectables are iron dextran, iron sucrose and ferric carboxymaltose. Iron dextran is a complex of iron and a carbohydrate called dextran. The various types of branded or generics are branded, generics that are used in various applications such as chronic kidney disease, inflammatory bowel disease, cancer and others and also by various end users such as hospitals, homecare, specialty clinics and others.

This report provides iron deficiency injectables market statistics, including iron deficiency injectables industry global market size, regional shares, competitors with an iron deficiency injectables market share, detailed iron deficiency injectables market segments, market trends and opportunities and any further data you may need to thrive in the iron deficiency injectables industry. This iron deficiency injectables market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The iron deficiency injectable market consists of sales of ferumoxide, sodium ferric gluconate and iron gluconate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.